CardioDx Receives $60,000,000 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=fb89b46b-70d8-4a82-a632-3ada85c12387&Preview=1 - Date
5/11/2011 - Company Name
CardioDx - Mailing Address
2500 Faber Place Palo Alto, CA 94303 - Company Description
Founded in 2004, CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. - Website
http://www.cardiodx.com - Transaction Type
Venture Equity - Transaction Amount
$60,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Funding will be used to expand reimbursement coverage in the United States for Corus™ CAD, the company’s blood-based gene expression test for obstructive coronary artery disease, and to continue development of future products in the field of cardiovascular genomic diagnostics. - M&A Terms
- Venture Investor
Longitude Capital Management - Venture Investor
JPMorgan Partners - Venture Investor
Acadia Woods Ventures - Venture Investor
Artiman Ventures - Venture Investor
Kleiner Perkins Caufield & Byers - Venture Investor
Mohr Davidow Ventures - Venture Investor
TPG Biotech - Venture Investor
Pappas Ventures - Venture Investor
DAG Ventures - Venture Investor
Asset Management Company
